PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.81
-0.08 (-1.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.89
Open7.91
Bid7.57 x 36900
Ask8.04 x 900
Day's Range7.75 - 7.94
52 Week Range5.01 - 9.42
Volume1,364,041
Avg. Volume1,534,723
Market Cap654.868M
Beta2.91
PE Ratio (TTM)N/A
EPS (TTM)-0.65
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • What Does Nektar Therapeutics’ Valuation Trend Indicate?
    Market Realist3 days ago

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY). 

  • Analysts Remain Bullish on Nektar Stock in August
    Market Realist4 days ago

    Analysts Remain Bullish on Nektar Stock in August

    Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.

  • Opko Health: Q2 Expenditures, Developments, Recommendations
    Market Realist9 days ago

    Opko Health: Q2 Expenditures, Developments, Recommendations

    In August, Opko Health completed the enrollment of its worldwide Phase 3 trial of somatrogon in children with GHD (growth hormone deficiency). In July, Health Canada approved Rayaldee, a product of Opko Health and its partner Vifor Fresenius Medical Care Renal Pharma (VFMCRP), for commercialization in the Canadian market for the treatment of individuals with secondary hyperthyroidism who are at stage 3 or stage 4 of chronic kidney disease and have vitamin D insufficiency. In July, Opko Health announced the completion of its enrollment of 110 candidates for the initiation of its Phase 2b dose escalation clinical study of OPK88003, an injectable oxyntomodulin drug with GLP-1 and glucagon dual agonist activity for the treatment of individuals with Type 2 diabetes and obesity.

  • How Opko Health Fared in the Second Quarter of 2018
    Market Realist9 days ago

    How Opko Health Fared in the Second Quarter of 2018

    In the second quarter, Opko Health reported a net loss of $6.2 million compared to a net loss of $16.9 million in Q2 2017. In the first half of 2018, it reported a net loss of $49.3 million compared to a net loss of $51.4 million in the first half of 2017. In the second quarter, it reported a diluted loss per share of $0.01 compared to a loss of $0.04 in Q2 2017. In the first half of 2018, it reported a diluted net loss per share of $0.09 compared to a diluted net loss per share of $0.11 in the first half of 2017.

  • GlobeNewswire11 days ago

    Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    The gross proceeds from the sale of the primary shares, before underwriting discounts and commissions and other offering expenses, are expected to be approximately $75 million. The offering is expected to close on or about August 10, 2018, subject to customary closing conditions. Progenics also granted the underwriters a 30-day option to purchase 1,363,636 additional shares of common stock on the same terms and conditions as the shares offered in the public offering.

  • GlobeNewswire11 days ago

    Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Progenics Pharmaceuticals, Inc. (PGNX) announced today that it is offering to sell shares of its common stock in an underwritten public offering pursuant to an effective shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual terms of the offering. Jefferies and Credit Suisse are acting as joint book-running managers for the proposed offering.

  • Benzinga17 days ago

    Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 31) Allakos Inc (NASDAQ: ALLK ) (listed July 19 following its IPO) ...

  • Associated Press18 days ago

    Progenics: 2Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 20 cents. The biopharmaceutical company posted revenue of $3.9 million in the period. Progenics shares have risen 34 percent since ...

  • GlobeNewswire18 days ago

    Following Azedra’s Approval, Progenics Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update

    AZEDRA ® Approved by U.S. Food and Drug Administration; U.S. Promotion Commences Top-Line Data from Phase 3 Trial for PSMA-Targeted SPECT/CT Imaging Agent 1404 Expected in Q3’ 18 Top-Line Data from Phase ...

  • FDA approves first non-surgical treatment for 2 rare cancers
    American City Business Journals18 days ago

    FDA approves first non-surgical treatment for 2 rare cancers

    The FDA's approval of Azedra followed clinical trails of the rare cancer therapy conducted at the University of Pennsylvania's Abramson Cancer Center in Philadelphia.

  • Benzinga18 days ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Apple Inc. (NASDAQ: AAPL ) is scheduled to release ...

  • ACCESSWIRE18 days ago

    Today’s Research Reports on Stocks to Watch: Progenics Pharmaceuticals and Arca Biopharma

    NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Biotech stocks Progenics and ARCA biopharma were both soaring on Monday. While ARCA had no news to explain its 40% climb, shares of Progenics soared higher after ...

  • 3 Big Stock Charts for Tuesday: Netflix, Unum Group and Dentsply Sirona
    InvestorPlace18 days ago

    3 Big Stock Charts for Tuesday: Netflix, Unum Group and Dentsply Sirona

    Stalwarts like Twitter (NYSE:TWTR) and Facebook (NASDAQ:FB), both of which set the pace for the rest of the market, continued last week’s tumbles. Progenics Pharmaceuticals (NASDAQ:PGNX) hammered out an 8% gain following news that one of its drugs won an approval from the FDA, and Advanced Micro Devices (NASDAQ:AMD) advanced more than 2% on Monday, still fueled by last week’s impressive earnings beat. With that as the backdrop, the stock charts of Netflix (NASDAQ:NFLX), Unum Group (NYSE:UNM) and Dentsply Sirona (NASDAQ:XRAY) say they’re the best-grounded trading setups … at least as it stands right now.

  • GlobeNewswire19 days ago

    Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma

    Progenics Pharmaceuticals, Inc. (PGNX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for AZEDRA (iobenguane I 131) 555 MBq/mL injection for intravenous use. AZEDRA, a radiotherapeutic, is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.  AZEDRA is the first and only approved therapy for this indication. AZEDRA can cause serious side effects including risk from radiation exposure, bone marrow problems and other cancers (myelosuppression and secondary malignancies), thyroid problems (hypothyroidism), elevations in blood pressure, kidney problems (renal toxicity), respiratory problems (pneumonitis), pregnancy warning (embryo-fetal toxicity), and fertility problems.

  • Reuters19 days ago

    FDA approves Progenics' treatment for rare adrenal gland tumors

    The U.S. Food and Drug Administration (FDA) on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of rare adrenal gland tumors, making it the first drug approved in the United States for this use. The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors - pheochromocytoma or paraganglioma - and require anti-cancer therapy, the FDA said https://bit.ly/2Ovz75p. The two tumor types affect the adrenal gland that releases the adrenaline hormone, which triggers the body's defense mechanism.

  • Reuters19 days ago

    FDA approves Progenics' treatment for two rare tumors

    The U.S. Food and Drug Administration on Monday approved Progenics Pharmaceuticals Inc's treatment for two types of tumors. The drug, Azedra, was approved to treat some patients above the age of 12 who ...

  • Benzinga19 days ago

    The Week Ahead: Apple And Tesla Earnings, FOMC Meeting, Sonos IPO

    Below is a list of notable corporate events for the week beginning July 30. Note, this list is not comprehensive and all dates are subject to change. All times are ET. View more earnings on AMZN Monday ...

  • ACCESSWIRE19 days ago

    Today's Research Reports on Trending Tickers: Progenics Pharmaceuticals and Gilead Sciences

    NEW YORK, NY / ACCESSWIRE / July 30, 2018 / U.S. markets plunged on Friday, after Twitter reported disappointing second quarter earnings and gross domestic product reflected fairly strong economic growth, ...

  • 3 Stocks That Could Double Your Money
    Motley Fool23 days ago

    3 Stocks That Could Double Your Money

    Find out why these three biotech stocks could be huge winners.

  • 3 Biotech Stocks With Major Catalysts Incoming
    Motley Fool2 months ago

    3 Biotech Stocks With Major Catalysts Incoming

    The third quarter of 2018 will be awfully exciting for owners of these three stocks.

  • 4 Drug and Biotech Stocks Awaiting FDA Decisions in July
    InvestorPlace2 months ago

    4 Drug and Biotech Stocks Awaiting FDA Decisions in July

    It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. Key FDA approvals in the first half included Amgen (NASDAQ:AMGN)/Novartis’s first CGRP antibody Aimovig/erenumab for prevention of migraine, Johnson & Johnson’s (NYSE:JNJ) next-generation oral androgen receptor (“AR”) inhibitor Erleada (apalutamide) for pre-metastatic prostate cancer (CRPC), Vertex Pharmaceuticals’ (NASDAQ:VRTX) third medicine to treat the underlying cause of CF, Symdeko, which is a combination of tezacaftor and ivacaftor and BioMarin Pharmaceuticals’ Palynziq to treat phenylketonuria (PKU). FDA Decision on Indivior’s Schizophrenia Injection RBP-7000: On Jul 28, the FDA is expected to give its decision on Indivior‘s (OTCMKTS:INVVY) RBP-7000, which has been developed for the treatment of schizophrenia.

  • 4 Drug and Biotech Stocks Awaiting FDA Decisions in July
    Zacks2 months ago

    4 Drug and Biotech Stocks Awaiting FDA Decisions in July

    In the first six months of the year, the FDA grants approval to 17 new treatments.

  • ACCESSWIRE2 months ago

    Complimentary Technical Snapshots on Puma Biotech and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on PBYI sign up now at www.wallstequities.com/registration. The Company's shares have gained 8.95% in the last month, 10.72% over the last three months, and 18.26% over the past year.

  • 3 Biotech Stocks With Major Potential Catalysts in July
    Motley Fool2 months ago

    3 Biotech Stocks With Major Potential Catalysts in July

    FDA approvals next month could be huge for these biotech stocks.

  • GlobeNewswire2 months ago

    Progenics Pharmaceuticals Completes Enrollment of Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™ in Prostate Cancer

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, today announced that it has completed enrollment in its Phase 2/3 OSPREY clinical trial evaluating the diagnostic accuracy of its PSMA-targeted PET/CT imaging agent, PyL™ (18F-DCFPyL), in prostate cancer. "The completion of enrollment for our PyL trial, ahead of schedule, marks an important milestone for the advancement of our PSMA-targeted pipeline," said Mark Baker, Chief Executive Officer of Progenics.